Drugs that contain Metformin Hydrochloride; Saxagliptin Hydrochloride

1. Drug name - KOMBIGLYZE XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(10 months from now)

CN1698601A ASTRAZENECA AB Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof
Mar, 2010

(12 years ago)

CN1427826A ASTRAZENECA AB Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof
Mar, 2021

(1 year, 6 months ago)

CN1213028C ASTRAZENECA AB Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof
Mar, 2021

(1 year, 6 months ago)

IN206543B ASTRAZENECA AB A Cyclopropyl-Fused Pyrrolidine-Based Compound
Mar, 2021

(1 year, 6 months ago)

IN200201154P3 ASTRAZENECA AB A Cyclopropyl-Fused Pyrrolidine-Based Compound
Mar, 2021

(1 year, 6 months ago)

EP2272825A3 ASTRAZENECA AB N-Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation
Mar, 2021

(1 year, 6 months ago)

EP2272825A2 ASTRAZENECA AB Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation
Mar, 2021

(1 year, 6 months ago)

EP2995615A1 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use
Mar, 2021

(1 year, 6 months ago)

EP2272825B1 ASTRAZENECA AB Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation
Mar, 2021

(1 year, 6 months ago)

EP2995615B1 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use
Mar, 2021

(1 year, 6 months ago)

EP1559710B1 ASTRAZENECA AB Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use
Mar, 2021

(1 year, 6 months ago)

EP1559710A3 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Process For Their Preparation And Their Use
Mar, 2021

(1 year, 6 months ago)

EP1559710A2 ASTRAZENECA AB Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use
Mar, 2021

(1 year, 6 months ago)

EP1261586B1 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use
Mar, 2026

(3 years from now)

EP1261586A2 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use
Mar, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8628799 ASTRAZENECA AB Coated tablet formulation and method Jul, 2025

(2 years from now)

US9339472 ASTRAZENECA AB Coated tablet formulation and method Jul, 2025

(2 years from now)

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
500MG;EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.